A live webcast
of the presentation
can be accessed
here

Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell-based therapies, today announced that Patrick Jeanmart, Chief Financial Officer and David Gilham, VP Research and Development of Celyad will present the THINK clinical trial status and a corporate overview at the upcoming 42nd Deutsche Bank Annual Health Care Conference on Thursday, May 4th, 2017 at 8:40 a.m. EST in Boston, MA.

Download press release(s)

Press release

77.47 Ko

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

Next News

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®